CD40L

IgG

Human

0. 5 mg/ml Storage

WB: Use at a concentration of 0. 5 - 1 µ g/ml.
ELISA: Use at a concentration of 2-3 µ g/ml. Not tested in other applications. Optimal dilutions/concentrations should be determined by the end user. CD40 ligand (CD40L) also known as CD154 gp39 and TRAP is a 33 kDa type II membrane glycoprotein expressed mainly on the cell surface of activated T lymphocytes but also exists as a soluble form extracellularly. CD40L is the ligand for CD40 a member of the TNF superfamily which is expressed on the cell surface of B cells macrophages/monocytes dendritic cells vascular endothelial cells and epithelial cells. CD40L plays an important role in B cell proliferation antibody class switching modulation of apoptosis in the germinal center through interaction with B cells expressing CD40 and activation of CD4+ T cells. Mutation within the CD40L gene is linked to hyper IgM syndrome an X-linked immunodeficiency disease that is characterized by elevated level of serum IgM and decreased level of other isotypes. CD40 also known as bp50 or CDW40 is a type I membrane protein found on the surface of B cells and primary carcinomas. It belongs to the TNF-R family. CD40 serves as the receptor for CD40 ligand (CD40L) a cytokine expressed on the cell surface of T cells. CD40 plays a critical role in B cell proliferation antibody class switching modulation of apoptosis in the germinal center through interaction with T cells expressing CD40L and activation of CD4+ T cells. Ligation of CD40 with its ligand preferentially induces stress-activated protein kinases in B lymphocytes.

Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa actin polymerization and an matrix metalloproteinases (MMP) inhibitor-sensitive pathway.

Cell membrane; Single-pass type II membrane protein.

Specifically expressed on activated CD4+ T-lymphocytes.

N-linked glycan is a mixture of high mannose and complex type. Glycan structure does not influence binding affinity to CD40.

Defects in CD40LG are the cause of X-linked immunodeficiency with hyper-IgM type 1 (HIGM1) [MIM:308230]; also known as X-linked hyper IgM syndrome (XHIM). HIGM1 is an immunoglobulin isotype switch defect characterized by elevated concentrations of serum IgM and decreased amounts of all other isotypes. Affected males present at an early age (usually within the first year of life) recurrent bacterial and opportunistic infections including Pneumocystis carinii pneumonia and intractable diarrhea due to cryptosporidium infection. Despite substitution treatment with intravenous immunoglobulin the overall prognosis is rather poor with a death rate of about 10% before adolescence.